Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug	anisomycin
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	ovarian cancer
ICD-0-3	C56.9
Methods	Microarray, qPCR, Western blot, Luciferase reporter assay, RIP
Sample	tumor tissues
Expression Pattern	differential expression
Function Description	there was a positive correlation between tumour angiogenesis and the number of CD44+ /CD133+ serous human ovarian cancer stem cells (HuOCSCs). Subsequently, it was confirmed that anisomycin significantly inhibited the proliferation, invasion, tumorigenic ability and tumour angiogenesis of HuOCSCs. Gene expression profiling by cDNA microarrays revealed that the expression levels of vascular endothelial cell markers, platelet-derived growth factors, Notch pathway components and 27 tumour angiogenesis-related genes were significantly decreased in the anisomycin-treated group compared with the control group. Further experiments demonstrated that the expres- sion levels of endogenous long non-coding RNA (lncRNA) maternally expressed 3 (Meg3) were significantly decreased in anisomycin-treated HuOCSCs, whereas the expression levels of microRNA (miR)-421 were significantly increased. The results of luciferase reporter assays indicated that, when miR-421 was overexpressed in cells, the luciferase activities of wild-type platelet derived growth factor receptor ? (PDGFRA) 3' untranslated region and Meg3 reporter plasmids were signif- icantly decreased. Overexpression of miR-421 in HuOCSCs significantly enhanced the anisomycin-mediated inhibition of HuOCSC proliferation.
Pubmed ID	31638182
Year	2019
Title	Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNA-Meg3/miR-421/PDGFRA axis

External Links